Bennett, C. L., Hoque, S., Olivieri, N., Taylor, M. A., Aboulafia, D., Lubaczewski, C., Bennett, A. C., Vemula, J., Schooley, B., Witherspoon, B. J., Godwin, A. C., Ray, P. S., Yarnold, P. R., Ausdenmoore, H. C., Fishman, M., Herring, G., Ventrone, A., Aldaco, J., Hrushesky, W. J., Restaino, J., Thomsen, H. S., Yarnold, P. R., Marx, R., Migliorati, C., Ruggiero, S., Nabhan, C., Carson, K. R., McKoy, J. M., Yang, Y. T., Schoen, M. W., Knopf, K., Martin, L., Sartor, O., Rosen, S., & Smith, W. K. (2021). consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). EClinicalMedicine, 31, . http://access.bl.uk/ark:/81055/vdc_100146367328.0x000002